203 related articles for article (PubMed ID: 17967910)
1. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.
Olson JA; Adler-Moore JP; Jensen GM; Schwartz J; Dignani MC; Proffitt RT
Antimicrob Agents Chemother; 2008 Jan; 52(1):259-68. PubMed ID: 17967910
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice.
Olson JA; Schwartz JA; Hahka D; Nguyen N; Bunch T; Jensen GM; Adler-Moore JP
Med Mycol; 2015 Feb; 53(2):107-18. PubMed ID: 25550388
[TBL] [Abstract][Full Text] [Related]
3. Nanosomal Amphotericin B is an efficacious alternative to Ambisome for fungal therapy.
Sheikh S; Ali SM; Ahmad MU; Ahmad A; Mushtaq M; Paithankar M; Mandal J; Saptarishi D; Sehgal A; Maheshwari K; Ahmad I
Int J Pharm; 2010 Sep; 397(1-2):103-8. PubMed ID: 20621173
[TBL] [Abstract][Full Text] [Related]
4. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
6. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
[TBL] [Abstract][Full Text] [Related]
7. Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.
Clemons KV; Schwartz JA; Stevens DA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4439-49. PubMed ID: 22687510
[TBL] [Abstract][Full Text] [Related]
8. Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.
Leenders AC; de Marie S; ten Kate MT; Bakker-Woudenberg IA; Verbrugh HA
J Antimicrob Chemother; 1996 Aug; 38(2):215-25. PubMed ID: 8877535
[TBL] [Abstract][Full Text] [Related]
9. Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.
Ruijgrok EJ; Fens MH; Bakker-Woudenberg IA; van Etten EW; Vulto AG
Antimicrob Agents Chemother; 2006 May; 50(5):1852-4. PubMed ID: 16641459
[TBL] [Abstract][Full Text] [Related]
10. Dectin-1-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy.
Ambati S; Ferarro AR; Kang SE; Lin J; Lin X; Momany M; Lewis ZA; Meagher RB
mSphere; 2019 Feb; 4(1):. PubMed ID: 30760610
[No Abstract] [Full Text] [Related]
11. Liposomal amphotericin B (AmBisome): efficacy and safety of low-dose therapy in pulmonary fungal infections.
Lequaglie C
J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():49-50. PubMed ID: 11801581
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.
Gavaldà J; Martín MT; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruíz I; Pahissa A
Antimicrob Agents Chemother; 2005 Jul; 49(7):3028-30. PubMed ID: 15980392
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis.
Allen SD; Sorensen KN; Nejdl MJ; Durrant C; Proffit RT
J Antimicrob Chemother; 1994 Dec; 34(6):1001-13. PubMed ID: 7730214
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis.
Kakeya H; Miyazaki Y; Senda H; Kobayashi T; Seki M; Izumikawa K; Yanagihara K; Yamamoto Y; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2008 May; 52(5):1868-70. PubMed ID: 18299412
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Clemons KV; Schwartz JA; Stevens DA
Med Mycol; 2011 Nov; 49(8):834-47. PubMed ID: 21539507
[TBL] [Abstract][Full Text] [Related]
16. Antifungal Liposomes Directed by Dectin-2 Offer a Promising Therapeutic Option for Pulmonary Aspergillosis.
Ambati S; Ellis EC; Pham T; Lewis ZA; Lin X; Meagher RB
mBio; 2021 Feb; 12(1):. PubMed ID: 33622715
[TBL] [Abstract][Full Text] [Related]
17. In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone.
Manavathu EK; Dimmock JR; Vashishtha SC; Cutright J; Chandrasekar PH
J Antimicrob Chemother; 1998 Nov; 42(5):585-90. PubMed ID: 9848441
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.
Bellocchio S; Gaziano R; Bozza S; Rossi G; Montagnoli C; Perruccio K; Calvitti M; Pitzurra L; Romani L
J Antimicrob Chemother; 2005 Feb; 55(2):214-22. PubMed ID: 15649994
[TBL] [Abstract][Full Text] [Related]
19. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
[TBL] [Abstract][Full Text] [Related]
20. Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis.
Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
J Antimicrob Chemother; 2004 Feb; 53(2):311-7. PubMed ID: 14729753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
